食管鳞癌HDAC1表达及其与临床病理参数的相关性
|
摘要
收集食管鳞癌及癌旁组织标本,制备组织芯片,采用免疫组化方法检测组蛋白去乙酰化酶1(HDAC1)表达情况,并统计分析HDAC1表达水平与患者临床病理参数间的相关性。结果显示,34组样本中食管鳞癌组织HDAC1阳性率(88%)显著高于癌旁组织(15%),表明HDAC1在食管鳞癌中普遍高表达,可能是食管鳞癌诊断的潜在标志物;HDAC1表达与性别、年龄、肿瘤分化程度和淋巴结转移等病理参数无显著相关性,表明HDAC1不是预测食管鳞癌患者预后的可靠标志物。
Esophageal squamous cell carcinoma(ESCC) and paracancerous tissue were collected to prepare tissue microarray, and HDAC1 expression was detected using immunohistochemistry stain, followed by analyzing the correlation between the expression of HDAC1 and clinicopathological parameters. The results showed that the high expression rate of HDAC1 in ESCC samples(88%) was significantly higher than that in paracancerous tissue samples(15%) in 34 pairs of samples, suggesting HDAC1 was generally highly expressed in ESCC and may be a potential marker for ESCC diagnosis. In additiion, there was no significant relevance between HDAC1 expression and the clinicopathological parameters including gender, age, degree of tumor differentiation and lymph node metastasis, indicating that HDAC1 was not a reliable marker for predicting the prognosis of patients with ESCC.
Esophageal squamous cell carcinoma(ESCC) and paracancerous tissue were collected to prepare tissue microarray, and HDAC1 expression was detected using immunohistochemistry stain, followed by analyzing the correlation between the expression of HDAC1 and clinicopathological parameters. The results showed that the high expression rate of HDAC1 in ESCC samples(88%) was significantly higher than that in paracancerous tissue samples(15%) in 34 pairs of samples, suggesting HDAC1 was generally highly expressed in ESCC and may be a potential marker for ESCC diagnosis. In additiion, there was no significant relevance between HDAC1 expression and the clinicopathological parameters including gender, age, degree of tumor differentiation and lymph node metastasis, indicating that HDAC1 was not a reliable marker for predicting the prognosis of patients with ESCC.
引文
[1] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65 (2): 87-108.
[2] 姚艺玮,何义富,季楚舒,等. ERCC1基因检测指导晚期食管癌个体化治疗的临床研究[J]. 安徽医科大学学报, 2015, 50 (5): 640-4.
[3] Cao L L, Yue Z, Liu L, et al. The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy[J]. Oncotarget, 2017, 8 (24): 39241-53.
[4] Li Y X, Edward S. HDACs and HDAC inhibitors in cancer development and therapy[J]. Cold Spring Harb Perspect Med, 2016, 6 (10): a026831.
[5] Goey A K, Sissung T M, Peer C J, et al. Pharmacogenomics and histone deacetylase inhibitors[J]. Pharmacogenomics, 2016, 17 (16): 1807-15.
[6] Eckschlager T, Plch J, Stiborova M, et al. Histone deacetylase inhibitors as anticancer drugs[J]. Int J Mol Sci, 2017, 18 (7): E1414.
[7] Wahaib K, Beggs A E, Campbell H, et al. Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma[J]. Am J Health Syst Pharm, 2016, 73 (7): 441-50.
[8] Yoon S, Eom G H. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases[J]. Chonnam Med J, 2016, 52: 1-11.
[9] Qin H T, Li H Q, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives[J]. Expert Opin Ther Pat, 2017, 27 (5): 621-36.
[10] Song M, He G, Wang Y, et al. Lentivirus-mediated knockdown of HDAC1 uncovers its role in esophageal cancer metastasis and chemosensitivity[J]. J Cancer, 2016, 7 (12): 1694-700.
[2] 姚艺玮,何义富,季楚舒,等. ERCC1基因检测指导晚期食管癌个体化治疗的临床研究[J]. 安徽医科大学学报, 2015, 50 (5): 640-4.
[3] Cao L L, Yue Z, Liu L, et al. The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy[J]. Oncotarget, 2017, 8 (24): 39241-53.
[4] Li Y X, Edward S. HDACs and HDAC inhibitors in cancer development and therapy[J]. Cold Spring Harb Perspect Med, 2016, 6 (10): a026831.
[5] Goey A K, Sissung T M, Peer C J, et al. Pharmacogenomics and histone deacetylase inhibitors[J]. Pharmacogenomics, 2016, 17 (16): 1807-15.
[6] Eckschlager T, Plch J, Stiborova M, et al. Histone deacetylase inhibitors as anticancer drugs[J]. Int J Mol Sci, 2017, 18 (7): E1414.
[7] Wahaib K, Beggs A E, Campbell H, et al. Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma[J]. Am J Health Syst Pharm, 2016, 73 (7): 441-50.
[8] Yoon S, Eom G H. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases[J]. Chonnam Med J, 2016, 52: 1-11.
[9] Qin H T, Li H Q, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives[J]. Expert Opin Ther Pat, 2017, 27 (5): 621-36.
[10] Song M, He G, Wang Y, et al. Lentivirus-mediated knockdown of HDAC1 uncovers its role in esophageal cancer metastasis and chemosensitivity[J]. J Cancer, 2016, 7 (12): 1694-700.